@article{Al_Saihati_H-2024_187714,
title = {MSC–extracellular vesicle microRNAs target host cell-entry receptors in COVID-19: in silico modeling for in vivo validation},
author = {Al Saihati, H. and Dessouky, A. and Salim, R. and Elgohary, I. and El-Sherbiny, M. and Ali, F. and Moustafa, M. and Shaheen, D. and Forsyth, N. and Badr, O. and Ebrahim, N.},
month = {sep},
year = {2024},
abstract = {Background Coronavirus disease 2019 (COVID-19) has created a global pandemic with significant morbidity and mortality. SARS-CoV-2 primarily infects the lungs and is associated with various organ complications. Therapeutic approaches to combat COVID-19, including convalescent plasma and vaccination, have been developed. However, the high mutation rate of SARS-CoV-2 and its ability to inhibit host T-cell activity pose challenges for effective treatment. Mesenchymal stem cells (MSCs) and their extracellular vesicles (MSCs–EVs) have shown promise in COVID-19 therapy because of their immunomodulatory and regenerative properties. MicroRNAs (miRNAs) play crucial regulatory roles in various biological processes and can be manipulated for therapeutic purposes.},
volume = {15},
journal = {Stem Cell Research & Therapy},
publisher = {Springer Nature},
url = {https://doi.org/10.1186/s13287-024-03889-9},
}
